Business
Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas
Pediatric Segment Growth Continues at 36% CAGR MINNEAPOLIS, June 14, 2022 (GLOBE NEWSWIRE) -- Improving access to life-saving fluid management therapies is a
About this update from Nuwellis, Inc.
[{"type":"text","content":"Pediatric Segment Growth Continues at 36% CAGR\nMINNEAPOLIS, June 14, 2022 (GLOBE NEWSWIRE) -- Improving access to life-saving fluid management therapies is a commitment by which Nuwellis, Inc. (Nasdaq: NUWE) stands. The company today announced its Aquadex SmartFlow® system is now available at two new pediatric hospitals in Florida and Arkansas. “By expanding access to Aquadex, we are another step closer to fulfilling our purpose-driven mission of positively transforming the lives of people suffering from fluid overload,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “Fluid overload can quickly lead to severe complications, and children have limited treatment options. Our current technology gives providers a tool they can rely on to remove excess fluid effectively and efficiently.1 This commitment to pediatric patients has resulted in significant growth for this segment of our business.” Acute kidney injury (AKI) and volume overload are common and are associated with morbidity and mortality in critically ill pediatric patients.234 These patients require gentle treatment approaches, which makes Aquadex uniquely beneficial for children. The Aquadex device is designed to remove small amounts of fluid over time and only requires 35 mL (around 2.5 tablespoons) of blood outside of the body. This is a key differentiator compared to other larger and more complex fluid management devices that can be taxing on the small bodies of children. Aquadex is cleared by the FDA for use in children weighing 20 kg or more. Nuwellis’ therapy meets an unmet need in pediatric patients, and the benefit of the clinically-proven5 technology can be demonstrated through its recent expansion to health centers in Florida and Arkansas. In addition to bringing its existing technology to new pediatric health centers, Nuwellis is currently developing a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. This device will be funded in part by a $1.7 million grant from the National Institutes of Health (NIH). Nuwellis has partnered with Minneapolis-based research and development firm Koronis Biomedical Technologies Corporation (KBT), the grant recipient, to design and develop a custom pediatric product that will enable clinicians to better care for babies with limited...